BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-11-27 07:45 |
BerGenBio - US Clinical Trial Update
|
English | 1.4 KB | ||
| 2017-11-17 07:00 |
BerGenBio ASA: Exercise of employee share options and increase of capital
|
English | 43.8 KB | ||
| 2017-11-17 07:00 |
BerGenBio ASA: Exercise of employee share options and increase of capital
|
English | 2.1 KB | ||
| 2017-11-17 06:00 |
BerGenBio ASA: Results for the Third Quarter 2017
|
English | 57.8 KB | ||
| 2017-11-17 06:00 |
BerGenBio ASA: Results for the Third Quarter 2017
|
English | 1.5 MB | ||
| 2017-11-17 06:00 |
BerGenBio ASA: Results for the Third Quarter 2017
|
English | 7.1 MB | ||
| 2017-11-17 06:00 |
BerGenBio ASA: Results for the Third Quarter 2017
|
English | 8.1 KB | ||
| 2017-11-16 10:15 |
BerGenBio to present at Jefferies 2017 London Healthcare Conference
|
English | 44.0 KB | ||
| 2017-11-16 10:15 |
BerGenBio to present at Jefferies 2017 London Healthcare Conference
|
English | 4.3 KB | ||
| 2017-11-14 07:00 |
BerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2…
|
English | 45.9 KB | ||
| 2017-11-14 07:00 |
BerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2…
|
English | 4.8 KB | ||
| 2017-11-10 10:00 |
BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast
|
Norwegian | 37.5 KB | ||
| 2017-11-10 10:00 |
BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast
|
English | 2.3 KB | ||
| 2017-11-01 13:05 |
Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor,…
|
English | 45.5 KB | ||
| 2017-11-01 13:05 |
Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor,…
|
English | 5.0 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
